Clinical Trials
20 trialsNCT05133076 2025-06-26
OIC1
BioGaia Pharma AB
Phase 2 Completed
NCT03720613 2025-02-12
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
BioDelivery Sciences International
Recruiting
NCT03638440 2024-06-17
NACASY
Kyowa Kirin Co., Ltd.
Completed
NCT01117051 2021-06-11
OIC
Takeda
Phase 3 Terminated
NCT00858754 2019-11-29
Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects
Bausch Health Americas, Inc.
Phase 4 Withdrawn
NCT02270983 2019-04-08
Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Forest Laboratories
Phase 2 Completed
NCT01696643 2018-11-15
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901302 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901328 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901341 2018-11-15
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01395524 2017-02-23
A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT00135577 2015-09-02
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT01323790 2015-06-02
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01309841 2015-06-01
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT01384292 2015-06-01
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
AstraZeneca
Phase 3 Terminated
NCT01336205 2014-10-20
Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
AstraZeneca
Phase 3 Completed
NCT00984334 2013-12-27
Naloxone SR Capsules in Patients With Opioid Induced Constipation
S.L.A. Pharma AG
Phase 2 Completed
NCT00399659 2012-05-01
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis
Phase 3 Terminated
NCT00365820 2012-04-20
Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain
Novartis
Phase 2/3 Terminated
NCT00414024 2012-04-20
Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.
Novartis
Phase 3 Terminated